Antitumor Effect of c-myc Antisense Phosphorothioate Oligodeoxynucleotides on Human Melanoma Cells In Vitro and in Mice

Background Phosphorothioate oligodeoxynucleotides ([S]ODNs) contain a modified internucleoside phosphate backbone. Antisense [S] ODNs targeted to specific oncogenes have been used with some therapeutic success in animal models of human leukemia; however, the potential for antisense [S]ODN treatment...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI : Journal of the National Cancer Institute 1996-04, Vol.88 (7), p.419-429
Hauptverfasser: Leonetti, Carlo, D' Agnano, Igea, Lozupone, Francesco, Valentini, Alessandra, Geiser, Tim, Zon, Gerald, Calabretta, Bruno, Citro, Gennaro, Zupi, Gabriella
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 429
container_issue 7
container_start_page 419
container_title JNCI : Journal of the National Cancer Institute
container_volume 88
creator Leonetti, Carlo
D' Agnano, Igea
Lozupone, Francesco
Valentini, Alessandra
Geiser, Tim
Zon, Gerald
Calabretta, Bruno
Citro, Gennaro
Zupi, Gabriella
description Background Phosphorothioate oligodeoxynucleotides ([S]ODNs) contain a modified internucleoside phosphate backbone. Antisense [S] ODNs targeted to specific oncogenes have been used with some therapeutic success in animal models of human leukemia; however, the potential for antisense [S]ODN treatment of solid tumors has only recently been explored. Purpose We evaluated the effects of antisense [S]ODNs targeted to the c-myc oncogene on the proliferation of human melanoma cells in vitro and on the growth of human melanoma xenografts in CD-1 nude (nu/nu) mice. Methods The effects of 15-mer [S]ODNs containing c-mycsense, c-myc antisense, and two different scrambled sequences on the proliferation and viability of cultures of three established human melanoma cell lines (M14, JR8, and PLF2) were determined by measuring cell numbers and use of the trypan blue exclusion test. The induction of apoptosis in these cells following treatment with [S]ODNs was evaluated by fluorescence-activated cell sorter (FACS) analysis. FACS analysis was also used to determine the effects of [S]ODN treatment on the proliferation of primary cultures of a human melanoma explant (NG cells). The expression of cMyc protein in cultured NG cells after treatment with [S]ODNs was examined by western blot analysis. The antitumor activity and the toxic effects of several [S]ODN treatment regimens were monitored by measuring differences in tumor weight (percent tumor weight inhibition), tumor growth rate (tumor growth inhibition), animal lifespan (percent increase in lifespan), the number of toxic deaths, and the median number of lung metastases in treated and control mice bearing NG xenografts. c-Myc protein expression in NG tumor cells following [S]ODN treatment was evaluated by FACS analysis, and the extent of apoptosis in these cells was determined by FACS analysis and morphologic examination. Results Treatment with antisense [S]ODNs, but not the others, inhibited the growth of all tested melanoma cultures in vitro; FACS analysis revealed that growth inhibition was associated with the induction of apoptosis. Antisense [S]ODN treatment also led to reduced cellular levels of c-Myc protein. In vivo, [S]ODN antitumor activity and toxicity were dose and schedule dependent; however, only antisense [S]ODNs exhibited antitumor activity. Mice bearing NG xenografts treated with antisense [S]ODNs showed a marked inhibition of tumor growth, a reduction in the number of lung metastases, and an increase in l
doi_str_mv 10.1093/jnci/88.7.419
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17039351</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17039351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-a966b38001ac0a25ecb8c3d9126e80e09869dccb8582f08452ca30b32783ef2a3</originalsourceid><addsrcrecordid>eNpdkc9rFDEUxwdR6rZ69CgEkd5mmx-TSXJsl9ptaakHFfESspk3btaZZE0y2P3vzdJlBUMgkM8n7z3yrap3BM8JVuxi4627kHIu5g1RL6oZaVpcU4L5y2qGMRW1lKJ5XZ2mtMFlKdqcVCeyJZIyNqv-XPrs8jSGiK77HmxGoUe2HncW7UkCnwB9Xoe0XYcY8toFkwE9Du5n6CA87fxkBwjZdZBQ8Gg5jcajBxiMD6NBCxiGhG49-uZyDMj4DrmCnYU31aveDAneHs6z6uun6y-LZX3_eHO7uLyvLScy10a17YpJjImx2FAOdiUt6xShLUgMWMlWdbZcckl7LBtOrWF4xaiQDHpq2Fl1_lx3G8PvCVLWo0u2jGU8hClpIjBTjJMifvhP3IQp-jKbpoxzUTYrUv0s2RhSitDrbXSjiTtNsN6nofdpaCm10CWN4r8_FJ1WI3RH-_D9hX88cJOsGfpoyvN01BiWBGP-r61LGZ6O2MRfuhVMcL38_kOru0Zc3dw9aMX-AhrMoes</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>235575573</pqid></control><display><type>article</type><title>Antitumor Effect of c-myc Antisense Phosphorothioate Oligodeoxynucleotides on Human Melanoma Cells In Vitro and in Mice</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Leonetti, Carlo ; D' Agnano, Igea ; Lozupone, Francesco ; Valentini, Alessandra ; Geiser, Tim ; Zon, Gerald ; Calabretta, Bruno ; Citro, Gennaro ; Zupi, Gabriella</creator><creatorcontrib>Leonetti, Carlo ; D' Agnano, Igea ; Lozupone, Francesco ; Valentini, Alessandra ; Geiser, Tim ; Zon, Gerald ; Calabretta, Bruno ; Citro, Gennaro ; Zupi, Gabriella</creatorcontrib><description>Background Phosphorothioate oligodeoxynucleotides ([S]ODNs) contain a modified internucleoside phosphate backbone. Antisense [S] ODNs targeted to specific oncogenes have been used with some therapeutic success in animal models of human leukemia; however, the potential for antisense [S]ODN treatment of solid tumors has only recently been explored. Purpose We evaluated the effects of antisense [S]ODNs targeted to the c-myc oncogene on the proliferation of human melanoma cells in vitro and on the growth of human melanoma xenografts in CD-1 nude (nu/nu) mice. Methods The effects of 15-mer [S]ODNs containing c-mycsense, c-myc antisense, and two different scrambled sequences on the proliferation and viability of cultures of three established human melanoma cell lines (M14, JR8, and PLF2) were determined by measuring cell numbers and use of the trypan blue exclusion test. The induction of apoptosis in these cells following treatment with [S]ODNs was evaluated by fluorescence-activated cell sorter (FACS) analysis. FACS analysis was also used to determine the effects of [S]ODN treatment on the proliferation of primary cultures of a human melanoma explant (NG cells). The expression of cMyc protein in cultured NG cells after treatment with [S]ODNs was examined by western blot analysis. The antitumor activity and the toxic effects of several [S]ODN treatment regimens were monitored by measuring differences in tumor weight (percent tumor weight inhibition), tumor growth rate (tumor growth inhibition), animal lifespan (percent increase in lifespan), the number of toxic deaths, and the median number of lung metastases in treated and control mice bearing NG xenografts. c-Myc protein expression in NG tumor cells following [S]ODN treatment was evaluated by FACS analysis, and the extent of apoptosis in these cells was determined by FACS analysis and morphologic examination. Results Treatment with antisense [S]ODNs, but not the others, inhibited the growth of all tested melanoma cultures in vitro; FACS analysis revealed that growth inhibition was associated with the induction of apoptosis. Antisense [S]ODN treatment also led to reduced cellular levels of c-Myc protein. In vivo, [S]ODN antitumor activity and toxicity were dose and schedule dependent; however, only antisense [S]ODNs exhibited antitumor activity. Mice bearing NG xenografts treated with antisense [S]ODNs showed a marked inhibition of tumor growth, a reduction in the number of lung metastases, and an increase in lifespan. Reduced levels of c-Myc protein and increased levels of apoptosis were also observed in NG tumor cells following antisense [S]ODN treatment. Conclusions Treatment of human melanoma cells and solid tumors with antisense [S]ODNs targeted to c-myc inhibits their growth and is associated with the induction of apoptosis. [J Natl Cancer Inst 1996;88:419–29]</description><identifier>ISSN: 0027-8874</identifier><identifier>EISSN: 1460-2105</identifier><identifier>DOI: 10.1093/jnci/88.7.419</identifier><identifier>PMID: 8618233</identifier><identifier>CODEN: JNCIEQ</identifier><language>eng</language><publisher>Cary, NC: Oxford University Press</publisher><subject>Animals ; Antineoplastic Agents - therapeutic use ; Apoptosis - drug effects ; Base Sequence ; Biochemistry ; Biological and medical sciences ; Blotting, Western ; Cell Cycle - drug effects ; Cell Division - drug effects ; Cellular biology ; Drug Administration Schedule ; Flow Cytometry ; Genes ; Genes, myc ; Humans ; Medical research ; Medical sciences ; Melanoma - drug therapy ; Melanoma - pathology ; Mice ; Mice, Nude ; Molecular Sequence Data ; Oligonucleotides, Antisense - therapeutic use ; Other treatments ; Proto-Oncogene Proteins c-myc - biosynthesis ; Proto-Oncogene Proteins c-myc - genetics ; RNA, Messenger - metabolism ; Rodents ; Skin cancer ; Thionucleotides ; Time Factors ; Transplantation, Heterologous ; Treatment. General aspects ; Tumor Cells, Cultured ; Tumors</subject><ispartof>JNCI : Journal of the National Cancer Institute, 1996-04, Vol.88 (7), p.419-429</ispartof><rights>1996 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Apr 3, 1996</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-a966b38001ac0a25ecb8c3d9126e80e09869dccb8582f08452ca30b32783ef2a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3081005$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8618233$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leonetti, Carlo</creatorcontrib><creatorcontrib>D' Agnano, Igea</creatorcontrib><creatorcontrib>Lozupone, Francesco</creatorcontrib><creatorcontrib>Valentini, Alessandra</creatorcontrib><creatorcontrib>Geiser, Tim</creatorcontrib><creatorcontrib>Zon, Gerald</creatorcontrib><creatorcontrib>Calabretta, Bruno</creatorcontrib><creatorcontrib>Citro, Gennaro</creatorcontrib><creatorcontrib>Zupi, Gabriella</creatorcontrib><title>Antitumor Effect of c-myc Antisense Phosphorothioate Oligodeoxynucleotides on Human Melanoma Cells In Vitro and in Mice</title><title>JNCI : Journal of the National Cancer Institute</title><addtitle>J Natl Cancer Inst</addtitle><description>Background Phosphorothioate oligodeoxynucleotides ([S]ODNs) contain a modified internucleoside phosphate backbone. Antisense [S] ODNs targeted to specific oncogenes have been used with some therapeutic success in animal models of human leukemia; however, the potential for antisense [S]ODN treatment of solid tumors has only recently been explored. Purpose We evaluated the effects of antisense [S]ODNs targeted to the c-myc oncogene on the proliferation of human melanoma cells in vitro and on the growth of human melanoma xenografts in CD-1 nude (nu/nu) mice. Methods The effects of 15-mer [S]ODNs containing c-mycsense, c-myc antisense, and two different scrambled sequences on the proliferation and viability of cultures of three established human melanoma cell lines (M14, JR8, and PLF2) were determined by measuring cell numbers and use of the trypan blue exclusion test. The induction of apoptosis in these cells following treatment with [S]ODNs was evaluated by fluorescence-activated cell sorter (FACS) analysis. FACS analysis was also used to determine the effects of [S]ODN treatment on the proliferation of primary cultures of a human melanoma explant (NG cells). The expression of cMyc protein in cultured NG cells after treatment with [S]ODNs was examined by western blot analysis. The antitumor activity and the toxic effects of several [S]ODN treatment regimens were monitored by measuring differences in tumor weight (percent tumor weight inhibition), tumor growth rate (tumor growth inhibition), animal lifespan (percent increase in lifespan), the number of toxic deaths, and the median number of lung metastases in treated and control mice bearing NG xenografts. c-Myc protein expression in NG tumor cells following [S]ODN treatment was evaluated by FACS analysis, and the extent of apoptosis in these cells was determined by FACS analysis and morphologic examination. Results Treatment with antisense [S]ODNs, but not the others, inhibited the growth of all tested melanoma cultures in vitro; FACS analysis revealed that growth inhibition was associated with the induction of apoptosis. Antisense [S]ODN treatment also led to reduced cellular levels of c-Myc protein. In vivo, [S]ODN antitumor activity and toxicity were dose and schedule dependent; however, only antisense [S]ODNs exhibited antitumor activity. Mice bearing NG xenografts treated with antisense [S]ODNs showed a marked inhibition of tumor growth, a reduction in the number of lung metastases, and an increase in lifespan. Reduced levels of c-Myc protein and increased levels of apoptosis were also observed in NG tumor cells following antisense [S]ODN treatment. Conclusions Treatment of human melanoma cells and solid tumors with antisense [S]ODNs targeted to c-myc inhibits their growth and is associated with the induction of apoptosis. [J Natl Cancer Inst 1996;88:419–29]</description><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Apoptosis - drug effects</subject><subject>Base Sequence</subject><subject>Biochemistry</subject><subject>Biological and medical sciences</subject><subject>Blotting, Western</subject><subject>Cell Cycle - drug effects</subject><subject>Cell Division - drug effects</subject><subject>Cellular biology</subject><subject>Drug Administration Schedule</subject><subject>Flow Cytometry</subject><subject>Genes</subject><subject>Genes, myc</subject><subject>Humans</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Melanoma - drug therapy</subject><subject>Melanoma - pathology</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Molecular Sequence Data</subject><subject>Oligonucleotides, Antisense - therapeutic use</subject><subject>Other treatments</subject><subject>Proto-Oncogene Proteins c-myc - biosynthesis</subject><subject>Proto-Oncogene Proteins c-myc - genetics</subject><subject>RNA, Messenger - metabolism</subject><subject>Rodents</subject><subject>Skin cancer</subject><subject>Thionucleotides</subject><subject>Time Factors</subject><subject>Transplantation, Heterologous</subject><subject>Treatment. General aspects</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><issn>0027-8874</issn><issn>1460-2105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc9rFDEUxwdR6rZ69CgEkd5mmx-TSXJsl9ptaakHFfESspk3btaZZE0y2P3vzdJlBUMgkM8n7z3yrap3BM8JVuxi4627kHIu5g1RL6oZaVpcU4L5y2qGMRW1lKJ5XZ2mtMFlKdqcVCeyJZIyNqv-XPrs8jSGiK77HmxGoUe2HncW7UkCnwB9Xoe0XYcY8toFkwE9Du5n6CA87fxkBwjZdZBQ8Gg5jcajBxiMD6NBCxiGhG49-uZyDMj4DrmCnYU31aveDAneHs6z6uun6y-LZX3_eHO7uLyvLScy10a17YpJjImx2FAOdiUt6xShLUgMWMlWdbZcckl7LBtOrWF4xaiQDHpq2Fl1_lx3G8PvCVLWo0u2jGU8hClpIjBTjJMifvhP3IQp-jKbpoxzUTYrUv0s2RhSitDrbXSjiTtNsN6nofdpaCm10CWN4r8_FJ1WI3RH-_D9hX88cJOsGfpoyvN01BiWBGP-r61LGZ6O2MRfuhVMcL38_kOru0Zc3dw9aMX-AhrMoes</recordid><startdate>19960403</startdate><enddate>19960403</enddate><creator>Leonetti, Carlo</creator><creator>D' Agnano, Igea</creator><creator>Lozupone, Francesco</creator><creator>Valentini, Alessandra</creator><creator>Geiser, Tim</creator><creator>Zon, Gerald</creator><creator>Calabretta, Bruno</creator><creator>Citro, Gennaro</creator><creator>Zupi, Gabriella</creator><general>Oxford University Press</general><general>Superintendent of Documents</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7QO</scope><scope>7TM</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>19960403</creationdate><title>Antitumor Effect of c-myc Antisense Phosphorothioate Oligodeoxynucleotides on Human Melanoma Cells In Vitro and in Mice</title><author>Leonetti, Carlo ; D' Agnano, Igea ; Lozupone, Francesco ; Valentini, Alessandra ; Geiser, Tim ; Zon, Gerald ; Calabretta, Bruno ; Citro, Gennaro ; Zupi, Gabriella</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-a966b38001ac0a25ecb8c3d9126e80e09869dccb8582f08452ca30b32783ef2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Apoptosis - drug effects</topic><topic>Base Sequence</topic><topic>Biochemistry</topic><topic>Biological and medical sciences</topic><topic>Blotting, Western</topic><topic>Cell Cycle - drug effects</topic><topic>Cell Division - drug effects</topic><topic>Cellular biology</topic><topic>Drug Administration Schedule</topic><topic>Flow Cytometry</topic><topic>Genes</topic><topic>Genes, myc</topic><topic>Humans</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Melanoma - drug therapy</topic><topic>Melanoma - pathology</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Molecular Sequence Data</topic><topic>Oligonucleotides, Antisense - therapeutic use</topic><topic>Other treatments</topic><topic>Proto-Oncogene Proteins c-myc - biosynthesis</topic><topic>Proto-Oncogene Proteins c-myc - genetics</topic><topic>RNA, Messenger - metabolism</topic><topic>Rodents</topic><topic>Skin cancer</topic><topic>Thionucleotides</topic><topic>Time Factors</topic><topic>Transplantation, Heterologous</topic><topic>Treatment. General aspects</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leonetti, Carlo</creatorcontrib><creatorcontrib>D' Agnano, Igea</creatorcontrib><creatorcontrib>Lozupone, Francesco</creatorcontrib><creatorcontrib>Valentini, Alessandra</creatorcontrib><creatorcontrib>Geiser, Tim</creatorcontrib><creatorcontrib>Zon, Gerald</creatorcontrib><creatorcontrib>Calabretta, Bruno</creatorcontrib><creatorcontrib>Citro, Gennaro</creatorcontrib><creatorcontrib>Zupi, Gabriella</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>JNCI : Journal of the National Cancer Institute</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leonetti, Carlo</au><au>D' Agnano, Igea</au><au>Lozupone, Francesco</au><au>Valentini, Alessandra</au><au>Geiser, Tim</au><au>Zon, Gerald</au><au>Calabretta, Bruno</au><au>Citro, Gennaro</au><au>Zupi, Gabriella</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antitumor Effect of c-myc Antisense Phosphorothioate Oligodeoxynucleotides on Human Melanoma Cells In Vitro and in Mice</atitle><jtitle>JNCI : Journal of the National Cancer Institute</jtitle><addtitle>J Natl Cancer Inst</addtitle><date>1996-04-03</date><risdate>1996</risdate><volume>88</volume><issue>7</issue><spage>419</spage><epage>429</epage><pages>419-429</pages><issn>0027-8874</issn><eissn>1460-2105</eissn><coden>JNCIEQ</coden><abstract>Background Phosphorothioate oligodeoxynucleotides ([S]ODNs) contain a modified internucleoside phosphate backbone. Antisense [S] ODNs targeted to specific oncogenes have been used with some therapeutic success in animal models of human leukemia; however, the potential for antisense [S]ODN treatment of solid tumors has only recently been explored. Purpose We evaluated the effects of antisense [S]ODNs targeted to the c-myc oncogene on the proliferation of human melanoma cells in vitro and on the growth of human melanoma xenografts in CD-1 nude (nu/nu) mice. Methods The effects of 15-mer [S]ODNs containing c-mycsense, c-myc antisense, and two different scrambled sequences on the proliferation and viability of cultures of three established human melanoma cell lines (M14, JR8, and PLF2) were determined by measuring cell numbers and use of the trypan blue exclusion test. The induction of apoptosis in these cells following treatment with [S]ODNs was evaluated by fluorescence-activated cell sorter (FACS) analysis. FACS analysis was also used to determine the effects of [S]ODN treatment on the proliferation of primary cultures of a human melanoma explant (NG cells). The expression of cMyc protein in cultured NG cells after treatment with [S]ODNs was examined by western blot analysis. The antitumor activity and the toxic effects of several [S]ODN treatment regimens were monitored by measuring differences in tumor weight (percent tumor weight inhibition), tumor growth rate (tumor growth inhibition), animal lifespan (percent increase in lifespan), the number of toxic deaths, and the median number of lung metastases in treated and control mice bearing NG xenografts. c-Myc protein expression in NG tumor cells following [S]ODN treatment was evaluated by FACS analysis, and the extent of apoptosis in these cells was determined by FACS analysis and morphologic examination. Results Treatment with antisense [S]ODNs, but not the others, inhibited the growth of all tested melanoma cultures in vitro; FACS analysis revealed that growth inhibition was associated with the induction of apoptosis. Antisense [S]ODN treatment also led to reduced cellular levels of c-Myc protein. In vivo, [S]ODN antitumor activity and toxicity were dose and schedule dependent; however, only antisense [S]ODNs exhibited antitumor activity. Mice bearing NG xenografts treated with antisense [S]ODNs showed a marked inhibition of tumor growth, a reduction in the number of lung metastases, and an increase in lifespan. Reduced levels of c-Myc protein and increased levels of apoptosis were also observed in NG tumor cells following antisense [S]ODN treatment. Conclusions Treatment of human melanoma cells and solid tumors with antisense [S]ODNs targeted to c-myc inhibits their growth and is associated with the induction of apoptosis. [J Natl Cancer Inst 1996;88:419–29]</abstract><cop>Cary, NC</cop><pub>Oxford University Press</pub><pmid>8618233</pmid><doi>10.1093/jnci/88.7.419</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0027-8874
ispartof JNCI : Journal of the National Cancer Institute, 1996-04, Vol.88 (7), p.419-429
issn 0027-8874
1460-2105
language eng
recordid cdi_proquest_miscellaneous_17039351
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals
subjects Animals
Antineoplastic Agents - therapeutic use
Apoptosis - drug effects
Base Sequence
Biochemistry
Biological and medical sciences
Blotting, Western
Cell Cycle - drug effects
Cell Division - drug effects
Cellular biology
Drug Administration Schedule
Flow Cytometry
Genes
Genes, myc
Humans
Medical research
Medical sciences
Melanoma - drug therapy
Melanoma - pathology
Mice
Mice, Nude
Molecular Sequence Data
Oligonucleotides, Antisense - therapeutic use
Other treatments
Proto-Oncogene Proteins c-myc - biosynthesis
Proto-Oncogene Proteins c-myc - genetics
RNA, Messenger - metabolism
Rodents
Skin cancer
Thionucleotides
Time Factors
Transplantation, Heterologous
Treatment. General aspects
Tumor Cells, Cultured
Tumors
title Antitumor Effect of c-myc Antisense Phosphorothioate Oligodeoxynucleotides on Human Melanoma Cells In Vitro and in Mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T17%3A31%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antitumor%20Effect%20of%20c-myc%20Antisense%20Phosphorothioate%20Oligodeoxynucleotides%20on%20Human%20Melanoma%20Cells%20In%20Vitro%20and%20in%20Mice&rft.jtitle=JNCI%20:%20Journal%20of%20the%20National%20Cancer%20Institute&rft.au=Leonetti,%20Carlo&rft.date=1996-04-03&rft.volume=88&rft.issue=7&rft.spage=419&rft.epage=429&rft.pages=419-429&rft.issn=0027-8874&rft.eissn=1460-2105&rft.coden=JNCIEQ&rft_id=info:doi/10.1093/jnci/88.7.419&rft_dat=%3Cproquest_cross%3E17039351%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=235575573&rft_id=info:pmid/8618233&rfr_iscdi=true